BioMarin Pharmaceutical Hits Day High with 7.95% Surge in Stock Price

BioMarin Pharmaceutical, Inc. has experienced a significant uptick in its stock performance, gaining 7.95% on August 10, 2026. The stock reached an intraday high of USD 69.27, marking a notable achievement for the small-cap company in the Pharmaceuticals & Biotechnology sector. In terms of performance metrics, BioMarin has shown resilience over various time frames. Over the past week, the stock has surged by 14.81%, and it has delivered a 16.51% increase over the past month. Year-to-date, the stock has risen by 15.9%, outperforming the S&P 500, which has seen a gain of 13.26%. However, it is important to note that the stock has underperformed over the longer term, with a three-year decline of 24.23% compared to the S&P 500's impressive 73.49% increase. Despite the recent gains, the company faces challenges, including a decline in pre-tax profit and net profit in its latest quarterly results. With a market capitalization of USD 10,412 million and a price-to-earnings ratio of 14.00, BioMarin continues to navigate a competitive landscape while maintaining a return on equity of 11.94%.